Abstract: In one embodiment, a method of building an optimized color flow high parameter reagent 20-color panel for detection of aberrant cells in acute myeloid leukemia (AML) is disclosed using a full spectrum flow cytometer. In another embodiment, a reagent kit for detection of aberrant cells in acute myeloid leukemia (AML) is disclosed for use with a full spectrum flow cytometer.

Abstract: Provided herein are bioactive molecule conjugates, preparation methods and use thereof, particularly bioactive molecule conjugates (such as antibody-drug conjugates and small molecule drug conjugates) obtained by improved coupling of a drug and a targeting moiety, as well as their preparation method and use for the treatment of a disease associated with an abnormal cell activity.

Abstract: Embodiments of the present disclosure generally relate to methods for forming a waveguide. Methods may include measuring a waveguide substrate, the waveguide having a substrate thickness distribution; and depositing an index-matched layer onto a surface of the waveguide, the index-matched layer having a first surface disposed on the waveguide substrate and a second surface opposing the first surface, wherein the index-matched layer is disposed only over a portion of the waveguide substrate, and a device slope of a second surface of the index-matched layer is substantially the same as the waveguide slope of the first surface of the waveguide.

Abstract: The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also relates to a preparation method for the solid and the pharmaceutical composition thereof, and an application thereof in the treatment of mental diseases. According to the present disclosure, the lurasidone solid prepared has controllable particle size and has Dv5O particle size of 6 ?m to 110 ?m. The good particle size stability can also he maintained in the pharmaceutical composition. The lurasidone suspension preparation obtained by the method is fast-acting, has a long sustained release period, and can effectively reduce the risk caused by poor patient compliance.

Abstract: A server computer obtains a plurality of user features, a plurality of service provider features, and a model. The server computer inputs the plurality of user features and the plurality of service provider features into the model. The server computer updates the model to form an updated model. The server computer determines a plurality of carts using the updated model. Each cart of the plurality of carts includes one or more items. The server computer provides one or more carts of the plurality of carts to an end user device. The server computer receives a selection of a cart of the one or more carts or a modification thereof. The server computer processes the selection by facilitating preparation and delivery of the one or more items in the cart. The server computer updates the updated model using data related to the cart to form a subsequent model.